Premium
Flex Pharma, Inc. (FLKS)
NASDAQ
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Flex Pharma, Inc. (Nasdaq: FLKS) today announced that its stockholders approved all proposals relating to its planned merger with Salarius Pharmaceuticals, LLC at Flex Pharma’s special meeting of...
Flex Pharma, Inc. (Nasdaq: FLKS) today announced that on or about June 27, 2019 it will mail a supplement (the “Supplement”) to its proxy materials to provide stockholders with updated...
Flex Pharma, Inc. (NASDAQ: FLKS), today announced its financial results for the three months ended March 31, 2019. On January 3, 2019, Flex Pharma (the "Company") and Salarius...
Flex Pharma, Inc. (NASDAQ: FLKS), today announced its financial results for the three months and fiscal year ended December 31, 2018. On January 3, 2019, Flex Pharma (the "Company") and...
– Lead Candidate in Clinical Trial for Treating Ewing Sarcoma – – Salarius Completes $6.4 Million Private Placement – – Conference Call and Live Audio Webcast Scheduled for Today at...
Asceneuron Appoints Dr. Thomas C. Wessel as Chief Medical Officer PR Newswire LAUSANNE, Switzerland and CAMBRIDGE, MA., December 6, 2018 LAUSANNE, Switzerland and CAMBRIDGE, MA., December 6, 2018...
Flex Pharma, Inc. (NASDAQ: FLKS), today announced its financial results for the three months ended September 30, 2018. On June 13, 2018, the Company announced that it was ending its...
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Flex Pharma, Inc. ("Flex Pharma" or the "Company...
Flex Pharma, Inc. (NASDAQ: FLKS), today announced its financial results for the three months ended June 30, 2018. On June 13, 2018, the Company announced that it was ending its ongoing...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
